Bulk Inquiry
MLN9708
- Ixazomib citrate
Axon 2557
CAS:
1201902-80-8
Purity:
99%
- Soluble in DMSO
- MF: C20H23BCl2N2O9
- MW: 517.12
Description
MLN9708 is the citrate prodrug of MLN2238 (Ixazomib; Axon 2556), a reversible inhibitor of the β5 catalytic site of the 20S proteasome. It is converted to the active proteasome inhibitor and is used to model clinically relevant ixazomib pharmacology.
Proteasome inhibition disrupts degradation of ubiquitinated proteins, driving proteotoxic stress, cell-cycle arrest and apoptosis in sensitive tumor cells. MLN9708 is useful for studying prodrug-to-active inhibitor relationships and proteasome-targeted anticancer mechanisms.
Key Features
- Prodrug of the active proteasome inhibitor MLN2238
- Targets β5 activity of the 20S proteasome after conversion
- Clinically relevant ixazomib pharmacology
- Induces proteotoxic stress and antitumor responses in reported models
Applications
- Proteasome inhibitor research
- Ixazomib prodrug pharmacology
- Multiple myeloma and oncology studies
- Ubiquitin-proteasome pathway assays
More Information
| Parent CAS No. | 1201902-80-8 |
|---|---|
| Chemical Name | 4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid |
| MFCD | MFCD18251437 |
| Short Description | Proteasome inhibitor |
MLN9708
ixazomib prodrug of proteasome inhibitor MLN2238
Ixazomib citrate
MLN-9708
MLN 9708
Ubiquitin
Proteasome 20S
β5 subunit
B-cell lymphoma
ixazomib prodrug of proteasome
Inhibitor
Proteasome inhibitor research
Ixazomib prodrug pharmacology
Multiple myeloma and oncology studies
Ubiquitin-proteasome pathway assays
apoptosis
protein degradation
ubiquitin signaling
multiple myeloma
cancer biology
enzyme pharmacology
CAS 1201902-80-8
Axon Medchem
Axon 2557
Supplier
Vendor
References
- E Kupperman et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.Cancer Res. 2010 Mar 1;70(5):1970-80.
- JJ Gu et al. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive….Anticancer Drugs. 2013 Nov;24(10):1030-8.
- N Shah et al. Ixazomib: an oral proteasome inhibitor for the treatment of multiple myeloma. Exp. Opin. Orph. Drugs (2016), 4(1), 105-113.
Other Categories
Get a Quote for
Loading...